Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs On track to begin a Phase 2a trial in the second half of 2023 with CC-42344 for the treatment of pandemic and seasonal influenza ASelected the novel protease inhibitor CDI-988 as development lead in...

Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs BOTHELL, Wash., May 15, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the three months ended March 31, 2023 and provides...

The antiviral drugs market is anticipated to grow at a CAGR of 6.3% during the period 2022-2035, claims Roots Analysis London, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Antiviral Drugs Market, 2022 – 2035” report to its list of offerings. The recent COVID-19 pandemic has...